Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jonathan S. Foot"'
Autor:
Lilian McNab, Andrew Wright, Scott Borthwick, Maria Ieva, Emma J. Rozgowska, Hamish McNab, Jonathan S. Foot
Publikováno v:
Arkivoc. 2020:161-175
Autor:
Jonathan S, Foot, Alberto, Buson, Mandar, Deodhar, Alison D, Findlay, Alan D, Robertson, Craig I, Turner, Tin, Yow, Wenbin, Zhou, Wolfgang, Jarolimek
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 74:128942
The discovery of a dual MAO-B/SSAO inhibitor PXS-5131 is reported. The compound offers a compact and rigid three-dimensional structure with superior selectivity over MAO-A. Potency and selectivity are linked to both the double bond geometry and stere
Publikováno v:
British Journal of Pharmacology. 174:2302-2317
Background and Purpose Neuroinflammation is initiated by a variety of stimuli including infections, sepsis, neurodegenerative diseases or traumatic brain injury and, if not adequately controlled, can lead to various degrees of neuronal damage and beh
Autor:
Thomas R. Cox, Paul Timpson, Lidia E. Leonte, Lukram Babloo Singh, Wolfgang Jarolimek, Joan Chang, Janine T. Erler, Morghan C. Lucas, Jonathan S. Foot, Mandar Deodhar, Marc Garcia-Montolio, Alison D. Findlay
Publikováno v:
Chang, J, Lucas, M C, Leonte, L E, Garcia-Montolio, M, Singh, L B, Findlay, A D, Deodhar, M, Foot, J S, Jarolimek, W, Timpson, P, Erler, J T & Cox, T R 2017, ' Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer ', Oncotarget . https://doi.org/10.18632/oncotarget.15257
Chang, J, Lucas, M C, Leonte, L E, Garcia-Montolio, M, Singh, L B, Findlay, A D, Deodhar, M, Foot, J S, Jarolimek, W, Timpson, P, Erler, J T & Cox, T R 2017, ' Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer ', OncoTarget, vol. 8, no. 16, pp. 26066-26078 . https://doi.org/10.18632/oncotarget.15257
Oncotarget
Chang, J, Lucas, M C, Leonte, L E, Garcia-Montolio, M, Singh, L B, Findlay, A D, Deodhar, M, Foot, J S, Jarolimek, W, Timpson, P, Erler, J T & Cox, T R 2017, ' Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer ', OncoTarget, vol. 8, no. 16, pp. 26066-26078 . https://doi.org/10.18632/oncotarget.15257
Oncotarget
// Joan Chang 1 , Morghan C. Lucas 2 , Lidia E. Leonte 1 , Marc Garcia-Montolio 1 , Lukram Babloo Singh 1 , Alison D. Findlay 3 , Mandar Deodhar 3 , Jonathan S. Foot 3 , Wolfgang Jarolimek 3 , Paul Timpson 2 , Janine T. Erler 1 , Thomas R. Cox 1, 2 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d1ecaaf3616c775c04eb52cde9a905
https://doi.org/10.18632/oncotarget.15257
https://doi.org/10.18632/oncotarget.15257
Autor:
Ama-Tawiah Essilfie, Philip M. Hansbro, Andrew G. Jarnicki, Wolfgang Jarolimek, Wheeldon K, Jonathan S. Foot, Heidi Schilter, Gang Liu, Yow Tt
Publikováno v:
British Journal of Pharmacology. 173:3161-3175
Background and Purpose Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death, often induced by cigarette smoking (CS). It is characterized by pulmonary inflammation and fibrosis that impairs lung function. Existing treatm
Autor:
Jonathan S. Foot, Heidi Schilter, Wolfgang Jarolimek, Lívia D. Tavares, Joerg Mattes, Angélica T. Vieira, Remo Castro Russo, Adam Collison, Tin T Yow, Mauro M. Teixeira
Publikováno v:
Respiratory Research
© Schilter et al. Background and purpose: The persistent influx of neutrophils into the lung and subsequent tissue damage are characteristics of COPD, cystic fibrosis and acute lung inflammation. VAP-1/SSAO is an endothelial bound adhesion molecule
Autor:
Andrew Holt, Jonathan S. Foot, Craig Ivan Turner, Aldo Olivieri, Ian A. McDonald, Diego Silva, Ellen M. van Dam, Mandar Deodhar, Ping Yin
Publikováno v:
Bioorganicmedicinal chemistry letters. 22(12)
A new class of 3-fluoroallyl amine-based SSAO/VAP-1 inhibitors is reported. These compounds have excellent selectivity over diamine oxidase, MAO-A and MAO-B. Synthesis and SAR studies leading to compound 28 (PXS-4159A) are reported. The pharmacokinet
ChemInform Abstract: Protein-Protein Coupling and Its Application to Functional Red Cell Substitutes
Publikováno v:
ChemInform. 41
The need for an alternative to red cells for oxygen transport in transfusions has led to the creation of hemoglobin-based oxygen carriers, materials produced by chemical modification or genetic engineering of human or bovine hemoglobin. Modifications